Table 2 Risk factors associated with AEs of inactivated COVID-19 vaccine in HIV-infected adults after dose 1 and dose 2: multivariable logistic regression analysis
From: Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
Item | Dose 1 | Dose 2 | ||
|---|---|---|---|---|
Adjusted ORa (95% CI) | P | Adjusted ORa (95% CI) | P | |
Age | ||||
≤ 35 | Ref. | Ref. | ||
> 35 | 0.68 (0.37, 1.26) | 0.22 | 0.58 (0.22, 1.49) | 0.26 |
Gender | ||||
Male | Ref. | Ref. | ||
Female | 1.03 (0.32, 3.34) | 0.96 | 2.54 (0.62, 10.41) | 0.20 |
Comorbidities | ||||
No | Ref. | Ref. | ||
Yes | 0.66 (0.26, 1.70) | 0.39 | 1.85 (0.60, 5.71) | 0.28 |
PIs (LPV/r) | ||||
No | Ref. | Ref. | ||
Yes | 2.97 (0.86, 10.30) | 0.09 | 11.92 (2.63, 54.00) | 0.001 |
CD4 | ||||
≤ 350 | Ref. | Ref. | ||
> 350 | 1.71(0.72,4.09) | 0.23 | 1.26 (0.39, 4.13) | 0.70 |
HIV viral load | ||||
Undetectable | Ref. | Ref. | ||
Detectable | 0.74 (0.32, 1.69) | 0.47 | 0.58 (0.15, 2.24) | 0.43 |